Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Acclaims Corden Pharma for Achieving Excellence in Product Differentiation - Unique product mix and technical excellence distinguish Corden Pharma from the competition -
Frost & Sullivan Acclaims Corden Pharma for Achieving Excellence in Product Differentiation


PRZOOM - /newswire/ - London, United Kingdom, 2012/02/01 - Unique product mix and technical excellence distinguish Corden Pharma from the competition -

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan recognises Corden Pharma with the 2011 Western Europe Frost & Sullivan Award for Product Differentiation Excellence.

"Corden Pharma offers unparalleled value to pharmaceutical and biotechnology companies by custom manufacturing of complex pharmaceutical materials and drug products," notes Frost & Sullivan Research Analyst Aiswariya Chidambaram. "Leveraging proprietary technologies and flexible production equipment, the company offers its clients an extensive range of high quality products at cost-effective prices."

The company distinguishes itself from other contract manufacturing organisations (CMOs) by virtue of its technical excellence and unique product portfolio. Core competencies within custom manufacturing include APIs and Drug Product, highly potent peptides, amino acid derivatives and building blocks for peptide synthesis, synthetic phospholipids and lipid derivatives, polymers, carbohydrates, and leading innovations in pseudoproline dipeptides, an important tool in augmenting the efficiency of peptide synthesis.

"The company’s unique product mix comprising conventional and innovative amino acid and lipid derivatives, peptide building blocks, polymers and carbohydrates of highest purity at competitive cost, coupled with a business model emphasising technology leadership, quality and superior customer service is central to its outstanding performance," adds Aiswariya.

Manufacturing equipment is the keystone to Corden Pharma’s superior quality. While several custom manufacturers possess large capacity, Corden Pharma is not only capable of large volume production but also lays strong emphasis on the flexibility and adaptability of its equipment to suit the short- and long-term needs of developing complex materials.

The company’s approach towards the custom manufacturing market starts at the pre-clinical phase of the product concept and continues through to the development and commercialisation of the customer’s drug product or fine chemical. Appropriate analytical and regulatory services are offered throughout all stages of development.

"The production capacities of the company range from small kilo to tonne capacity, providing optimised value, cost considerations and supply chain management for each customer’s position in the commercialisation process," remarks Aiswariya "In addition, the company also support the regulatory requirements of its customers and continuously upgrades itself on the technological front."

Corden Pharma has pursued a consistent strategy of paying heed to its customers’ needs and meeting them successfully, which is evident from the transformation the company has undergone, since its inception. Being comprised of 6 GMP manufacturing facilities across Europe and the US acquired from well-known pharmaceutical and biotechnology companies, Corden Pharma provides customers global access to a combined legacy of excellence formed from each facility’s respective areas of expertise. For example, though Corden Pharma’s Swiss manufacturing facility initially started its operations with custom manufacturing of amino acids, peptides and lipids, it has gradually moved into conjugation (lipids and peptides through linkers, lipopeptides) based on customer requirements. Furthermore, it has introduced carbohydrate chemistry for the glycosylation projects of customers.

The company has also ventured into polymerization activities for pharmaceutical applications, requiring a.o. moisture-sensitive handling. Some of the new projects that Corden Pharma is venturing into, in alignment with the customer needs, include supporting development of vaccines and providing linkers with lipid, peptide and conjugate chemistries to include additional functional lipids for pharma and biotech companies.

The Product Differentiation Excellence Award is presented to the company that has demonstrated excellence in developing unique product features and functionality, in achieving superior customisation and in matching target market needs. The award lauds the brand perception of the uniqueness of the product.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Corden Pharma
Corden Pharma ( is a specialised contract manufacturer utilizing sophisticated technologies developed through years of proven experience that are ideal for the production of oral and sterile highly potent or antibiotic pharmaceutical products and their active ingredients. The company offers customised service packages which span the entire pharmaceutical product continuum from development and custom manufacturing of Active Pharmaceuticals Ingredients, formulation development, assistance with approval procedures, and commercial production of Drug Products, all the way to complete pharmaceutical logistics. Their manufacturing facilities located across Europe and in the US are audited by all relevant approval authorities, making Corden Pharma a premier partner for pharmaceutical and biotechnology companies worldwide.

About Frost & Sullivan
Frost & Sullivan (, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Frost & Sullivan Acclaims Corden Pharma for Achieving Excellence in Product Differentiation

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | Corden Pharma
Contact: Catherine Brassell 
+27(0)21 680 3267 catherine.brassell[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  NAKIVO, Inc.

Visit  Demyk Lightmod Products, Inc.

Visit  Intrinsic Executive Search Ltd

  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today